Myomo

Myomo, Inc. is a medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. It offers MyoPro, an upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. The company was founded by Stephen Kelly, John McBean, Mira Sahney, and Kailas N. Narendran on September 1, 2004 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Myomo reports 9% revenue growth in Q1 2024 earnings call

Myomo's Q1 2024 performance reflects revenue growth driven by favorable CMS developments, with plans to double manufacturing capacity and achieve cash flow breakeven by Q4 2024.
The company's strategic strengths lie in its focus on the prevalence group, international expansion, and commitment to market leadership through increased output and R&D investments.
Challenges include managing operating expenses, scaling manufacturing capacity, and meeting revenue targets amidst market competition and reimbursement rate fluctuations.
Opportunities abound in international growth, market expansion in Germany, and the potential for accelerated U.S. revenue, supported by investments in resources and R&D.

Myomo excels in Q2 with record revenues and global expansion

Myomo's Q2 2024 performance reflects strong revenue growth, operational efficiency gains, and strategic expansion initiatives.
The company's strengths lie in international revenue generation, production facility expansion plans, and commitment to meeting product demand.
Challenges include scaling production while ensuring quality, monitoring advertising ROI, and balancing R&D with operational needs.
Opportunities arise from investor engagement, increased advertising, and continued innovation to drive market presence and revenue growth.

Myomo reports record Q3 revenue, eyes global expansion and market partnerships

Myomo's Q3 performance showcased robust revenue growth, pipeline expansion, and strategic partnerships, positioning the company for sustained success and global expansion.
While facing operational losses, Myomo's strengths in product innovation, market expansion, and capacity planning provide a solid foundation for future growth and profitability.
Challenges in cost management, market penetration, and regulatory compliance need to be addressed, but the company's proactive approach to expansion and partnerships bodes well for seizing growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Myomo, Inc. is a wearable medical robotics company, which engages in the business of developing, designing, and producing myoelectric orthotics for people with neuromuscular disorders. The firm is also involved in selling products through various other sales channels including through orthotics and prosthetics providers, veterans’ administration, and to distributors in certain accounts and geographic markets. The company was founded by Stephen Kelly, John McBean, Mira Sahney, and Kailas N. Narendran on September 1, 2004 and is headquartered in Boston, MA.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it will report financial results for the third quarter ended September 30, 2020 on Tuesday, November 10, 2020 after the market close. The Company will host a conference call the same day, Tuesday, November 10, 2020 at 4:30 p.m. ET with

Myomo to Report Third Quarter Financial Results on November 10, 2020

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American:MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Harry Kovelman, MD, is joining the Company as its Chief Medical Officer, effective November 2. In this role, Dr. Kovelman will oversee Myomo's patient advocacy organization, which helps ensure MyoPro patients' clinical qualification for

Myomo Appoints Dr. Harry Kovelman as Chief Medical Officer

Myomo (MYO) is in the news Wednesday following an announcement about Medicare authorization that sent MYO stock soaring higher.
The post Myomo News: MYO Stock Surges 32% on Medicare Authorization appeared first on InvestorPlace.

Myomo News: MYO Stock Surges 32% on Medicare Authorization

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc.

Myomo Certified as Medicare Provider

Myomo® to Present at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference

Myomo® Extends and Strengthens its Global MyoPro™ Patent Portfolio

Myomo® Receives First Australian Insurance Authorization for MyoPro™

Myomo, Inc.'s (MYO) CEO Paul Gudonis on Q2 2020 Results - Earnings Call Transcript

Myomo Reports 2020 Second Quarter Financial Results

Myomo to Report Second Quarter Financial Results on August 10, 2020

Myomo, Inc. (MYO) CEO Paul Gudonis on Q1 2020 Results - Earnings Call Transcript

Myomo's (MYO) CEO Paul Gudonis on Q4 2019 Results - Earnings Call Transcript

Myomo, Inc. (MYO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Myomo, Inc. (MYO) Expected to Beat Earnings Estimates: Should You Buy?

Myomo Inc (NYSE: MYO) shares ran wild Tuesday and the momentum continued in Wednesday's session.

What's Behind Nanocap Biotech Myomo's 400% Rally In 2 Days?

Myomo, Inc. (MYO) CEO Paul Gudonis on Q3 2019 Results - Earnings Call Transcript

Myomo, Inc. (MYO) delivered earnings and revenue surprises of 0.00% and -53.31%, respectively, for the quarter ended September 2019.

Myomo, Inc. (MYO) Reports Q3 Loss, Misses Revenue Estimates

Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Myomo, Inc. (MYO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Myomo's (MYO) CEO Paul Gudonis on Q2 2019 Results - Earnings Call Transcript

Will Myomo, Inc. (MYO) Report Negative Q2 Earnings?

Myomo, Inc. (MYO) CEO Paul Gudonis on Q1 2019 Results - Earnings Call Transcript

Myomo, Inc. (MYO) delivered earnings and revenue surprises of 15.00% and -3.49%, respectively, for the quarter ended March 2019.

Myomo, Inc. (MYO) Reports Q1 Loss, Lags Revenue Estimates

Myomo, Inc. (MYO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

News for Myomo Stock (MYO)